Roche Pharmaceutical Development and Sales Overview

Tecentriq (atezolizumab, RG7446) Anti-PD-L1 cancer immunotherapy - hepatocellular carcinoma Indication Adjuvant hepatocellular carcinoma (HCC) Phase/study # of patients Design " ARM A: Tecentriq plus Avastin ARM B: Active surveillance ☐ Primary endpoint Recurrence-free survival ☐ FPI Q4 2019 Status CT Identifier Recruitment completed Q4 2021 Phase III IMbrave050 N=668 NCT04102098 PD-L1-Programmed cell death-ligand 1; ESMO-European Society for Medical Oncology; NEJM-New England Journal of Medicine; RTOR=Real time oncology review 72 Roche Oncology

View entire presentation